26 results on '"Pfeffer, Marc"'
Search Results
2. Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials
3. Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
4. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs
5. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
6. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial
7. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
8. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial
9. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
10. Associations Between Depressive Symptoms and HFpEF-Related Outcomes
11. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials
12. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
13. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure
14. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
15. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
16. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
17. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial
18. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial
19. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study
20. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
21. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial
22. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction
23. Left Ventricular Size, Mass, and Shape
24. Developing Therapies for Heart Failure With Preserved Ejection Fraction
25. Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction
26. PRAISE (Prospective Randomized Amlodipine Survival Evaluation) and Criticism ∗
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.